Skip to main content

Monitoring cancer stem cell dynamics and therapeutic response in BRCA2-deficient breast tumour cells

Project description

Cancer stem cell dynamics in BRCA2-deficient breast cancer

Heterozygous germline mutations in the breast cancer susceptibility genes (BRCA) 1 or 2 predispose to breast, ovarian, pancreatic and prostate cancers. Significant evidence has accumulated in recent years on vulnerabilities specific to BRCA1/2-deficient tumours leading to the development of targeted therapies including poly(ADP-ribose) polymerase (PARP) inhibitors. Recent studies suggest that BRCA2-deficient cells can acquire metastatic and tumour-initiating capacity. The EU-funded BRCAstem project intends to study the relationship between cancer stem cells (CSCs) and the response to PARP inhibitors and ionising radiation in cancer cell lines and patient-derived xenografts lacking BRCA2. This study will uncover the mechanisms driving cell plasticity in models of BRCA2 inactivation and evaluate CSC impact on the response of BRCA-mutated tumours to current targeted therapies.

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Net EU contribution
€ 224 933,76
Address
Wellington Square University Offices
OX1 2JD Oxford
United Kingdom

See on map

Region
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00